
Myth: Stem Cell Injections Can Regrow Lost Cartilage in an Arthritic Joint
4 min readKnee osteoarthritis MSC trials show pain and function benefits, but do not establish cartilage regeneration; imaging findings, adverse events and FDA limits.
An independent reference library on stem cell therapy and cancer immunotherapy research.
471 articles · 2 topics · 351 Stem Cell Research · 120 Cancer Immunotherapy
Step 1 — Topic
Step 2 — Category
All 471 articles

Knee osteoarthritis MSC trials show pain and function benefits, but do not establish cartilage regeneration; imaging findings, adverse events and FDA limits.

Autologous HSCT for severe refractory myasthenia gravis: durable remission signals, immune-reset biology, candidate profiles and substantial transplant risks.

Compare Type 1 and Type 2 diabetes cell-therapy research with gestational diabetes, MODY and complication studies, including trial results and approval limits.

Sleep restriction, inflammatory cytokines and osteoarthritis risk: what experimental and population studies show, and the limits of catch-up sleep and causation.

Crohn’s disease causes, symptoms, diagnosis and standard care, with darvadstrocel’s approval history, failed confirmatory trial and current cell-therapy limits.

Australia’s first reported CAR-T lupus case, international remission signals, trial-only access and the serious risks behind this early autoimmune research.

Advanced Therapies Week returns to San Diego in January 2027, spotlighting manufacturing, partnering and commercialization rather than clinical evidence.

Compare embryonic and adult stem cells by origin, potency, ethical considerations and clinical maturity, including investigational retinal and islet therapies.

A registry listing is not FDA endorsement. Learn how IND oversight, IRB approval, study design and fees distinguish clinical trials from data collection.

Patient stories can be sincere without proving efficacy. Learn how bias, placebo response and regression to the mean differ from controlled clinical evidence.

Dostarlimab’s accelerated rectal cancer approval offers organ preservation for a narrow biomarker-defined population, with interim response and safety caveats.

MSC and bone marrow injections for tennis elbow show encouraging small-study signals, but controlled evidence remains limited and no product is FDA-approved for this use.
Every feature article on regenmedreview carries a Sources block listing its references. Where the original source material included no external citations, that is stated explicitly rather than left blank.